A Randomized, Open-label, Controlled Clinical Study to Evaluate the Safety and Immunogenicity of Adsorbed Acellular Diphtheria, Tetanus and Pertussis Combined Vaccine Administered at Different Injection Sites in Healthy Infants and Young Children

INTERVENTION: Trial group:Trial group inoculation site and route: anterior lateral thigh, intramuscular injection.;Control group:Control group inoculation site and route: lateral aspect of the upper arm deltoid muscle, intramuscular injection.; CONDITION: Diphtheria, Tetanus, Pertussis PRIMARY OUTCOME: Seroconversion rates and geometric mean concentrations (GMCs) of each antibody 30 days after completion of the full primary immunization series; SECONDARY OUTCOME: Incidence of adverse events within 30 days following each vaccine dose;Incidence of serious adverse events within 6 months after completion of the full primary immunization series;Geometric Mean Fold Increases (GMFIs) of each antibody at Day 30 after completion of the full primary immunization series; INCLUSION CRITERIA: 1.Permanent healthy subjects aged 3 to 6 months; 2.Consent obtained from the volunteer’s guardian with a signed informed consent form; 3.The volunteer and their guardian are able to comply with the requirements of the clinical trial protocol; 4.No prior vaccination with diphtheria, tetanus and pertussis vaccine or combination vaccines containing its components; 5.Axillary temperature <= 37.0?;